Seres Therapeutics, Inc.

MCRB

Seres Therapeutics, Inc.

MCRB

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-05-18Shares Purchased (TTM):0Shares Sold (TTM):3,567

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:2,306,463Shares Outstanding:9,582,533Institutional Ownership Pct.:24.07%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	16	30	46	48	45	59	31	67	71	111	128	170
Short Term Investments	-	-	-	-	-	-	-	-	-	-	0	0
Inventory Net	-	-	-	-	-	-	-	-	53	42	30	19
Accounts Receivable Net Current	0	0	0	0	-	-	0	-	-	-	-	-
Assets Of Disposal Group Including Discontinued Op…	-	-	-	-	-	-	0	0	-	-	39	-
Prepaid Expense And Other Assets Current	1	2	3	3	2	4	6	6	6	5	8	9
Assets Current	42	32	49	52	49	66	39	73	149	165	175	214
Property Plant And Equipment Net	6	7	8	9	10	11	12	13	18	19	18	24
Operating Lease Right Of Use Asset	51	70	72	75	77	79	81	83	103	106	90	108
Restricted Cash Noncurrent	2	9	9	9	9	9	9	10	10	8	8	8
Restricted Investments Noncurrent	-	-	-	-	-	-	0	0	0	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	42	41	2	12
Assets	102	118	138	143	144	164	140	179	322	341	359	368
Liabilities And Stockhold…
Disposal Group Including Discontinued Operation As…	-	-	-	-	-	-	0	0	-	-	63	-
Liabilities Current
Accounts Payable Current	1	2	2	2	2	2	4	8	5	5	4	9
Operating Lease Liability Current	12	11	10	10	9	9	9	8	9	9	6	6
Notes Payable Current	-	-	-	-	-	-	-	-	-	-	0	0
Deferred Income	-	-	-	-	-	-	-	-	8	8	8	9
Liabilities Current	20	19	19	22	31	31	41	65	108	98	99	79
Operating Lease Liability Noncurrent	45	70	73	75	78	80	83	85	101	103	92	105
Other Liabilities Noncurrent	2	2	2	2	2	2	2	2	2	2	2	2
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	0	0	-	-	67	-
Liabilities	67	91	94	100	111	114	126	155	409	401	403	383
Long Term Notes Payable	-	-	-	-	-	-	0	0	102	102	102	101
Stockholders Equity
Derivative Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0	1	1
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	0	0	-	-	109	-
Additional Paid In Capital Common Stock	1,022	1,019	1,017	1,001	998	996	992	986	964	958	933	922
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	0	0	-	-	0	0	0	0	0
Retained Earnings Accumulated Deficit	-988	-992	-972	-957	-965	-945	-978	-962	-1,051	-1,018	-978	-937
Stockholders Equity	35	26	44	44	33	50	14	24	-87	-60	-45	-15
Liabilities And Stockholders Equity	102	118	138	143	144	164	140	179	322	341	359	368
Related Party	-	-	-	-	-	-	-	-	-	-	-	3
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	-	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	360	360	360	360	360	360	360	360	360	240	240	240
Common Stock Shares Issued	10	10	10	9	9	9	9	9	8	8	7	6
Shares Outstanding	10	10	10	9	9	9	9	9	8	8	7	6

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.40%	-5.60%	-33.80%	-	-	-	-	-	-	-	-	-
2025	-14.96%	9.77%	75.27%	37.40%	37.32%	29.49%	41.65%	15.35%	18.50%	2.43%	-15.91%	-19.12%
2024	33.51%	-3.34%	76.23%	15.22%	2.54%	-0.72%	39.49%	53.39%	43.22%	0.31%	-24.53%	-44.75%
2023	-	-	-	-15.38%	-44.52%	-67.83%	23.39%	36.27%	31.97%	-26.98%	-22.17%	-13.49%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.11	1.65	2.56	2.30	1.57	2.11	0.94	1.12	1.38	1.68	1.78	2.71
Quick Ratio	2.04	1.55	2.40	2.16	1.50	1.97	0.80	1.03	0.83	1.20	1.40	2.36
Working Capital	22.32M	12.49M	30.05M	29.10M	17.75M	34.76M	-2.55M	8.10M	40.98M	66.70M	76.75M	135.17M
Leverage & Debt
Debt to Equity	1.94	3.44	2.13	2.28	3.36	2.25	9.14	6.47	-4.69	-6.71	-8.99	-25.31
Interest Coverage TTM	-	-	-	-179.02	-189.85	-184.65	-98.15	-78.56	-83.25	-24.56	-25.01	-16.98
Debt Ratio	0.66	0.77	0.68	0.70	0.77	0.69	0.90	0.87	1.27	1.18	1.13	1.04
Efficiency & Turnover
Asset Turnover TTM	0.02	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.36	0.37
Days Sales Outstanding TTM	53.11	74.15	72.63	365.00	-	-	-	-	-	-	-	-
Receivables Turnover TTM	6.87	4.92	5.03	1.00	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	3.09	-4.89	0.64	-7.69	1.50	8.37	0.02	-7.40	-25.50	-11.32	-17.77	-19.76
Free Cash Flow Per Share TTM	-5.28	-4.42	0.10	-2.67	-6.90	-9.98	-19.18	-20.75	-24.37	-10.95	-19.58	-20.78
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-4,798.88%	-7,640.98%	-11,910.14%	-31,519.09%	-	-	-	-403,243.75%	-73,126.20%	-125.32%	-154.44%	-93.62%
Net Profit Margin TTM	1,600.21%	-4,088.84%	721.93%	-19,208.26%	-	-	-	-88,306.25%	-51,643.32%	-65.18%	-90.02%	-99.60%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	448.44%	-100.00%	-100.00%	-100.00%	-99.95%	-99.71%	2,380.87%	1,672.24%	780.89%
Net Income Growth (1Y)	129.12%	-164.29%	4,088.24%	19.30%	-106.81%	-188.23%	-100.12%	-55.40%	39.08%	-68.76%	-54.54%	-39.71%
EPS Growth (1Y)	106.40%	-158.39%	3,573.36%	3.95%	-105.90%	-174.06%	-100.10%	-62.52%	17.24%	-73.09%	-61.62%	-42.42%
Valuation Metrics
P/E TTM	2.54	-1.81	23.14	-2.50	7.39	1.67	949.53	-2.56	-0.57	-1.37	-1.58	-2.41
P/B TTM	2.22	3.21	2.98	3.86	2.95	2.41	9.37	6.04	-1.26	-1.89	-4.00	-20.19
P/S TTM	40.67	74.10	167.07	480.11	-	-	-	2,256.28	293.30	0.89	1.42	2.40
Market Cap	76.58M	85.00M	131.82M	168.52M	97.14M	121.85M	129.14M	144.40M	109.69M	113.08M	179.20M	305.33M
Enterprise Value	58.74M	46.50M	77.39M	112.21M	43.10M	54.33M	89.67M	67.71M	131.08M	95.48M	144.60M	228.37M
Calculated Values
Free Cash Flow TTM	-51.30M	-42.37M	865.00K	-23.37M	-60.38M	-86.82M	-148.99M	-158.39M	-184.64M	-79.98M	-125.33M	-133.31M
Net Debt	-17.84M	-38.50M	-54.43M	-56.31M	-54.05M	-67.52M	-39.46M	-76.70M	21.39M	-17.61M	-34.61M	-76.96M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-18Sale

Owner: Brady, Kelly

Title: See Remarks

Shares: 59

Price/Share: $7.53

Value: $444.27

Shares Owned: 8,562

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Henn, Matthew R

Title: See Remarks

Shares: 77

Price/Share: $7.53

Value: $579.81

Shares Owned: 7,838

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Shaff, Eric D.

Title: -

Shares: 259

Price/Share: $7.53

Value: $1,950.27

Shares Owned: 12,040

Relationship: Director

Ownership: Direct

2026-05-18Sale

Owner: Desrosier, Thomas

Title: See Remarks

Shares: 79

Price/Share: $7.53

Value: $594.87

Shares Owned: 7,954

Relationship: Officer

Ownership: Direct

2026-02-15Sale

Owner: Young, Teresa L.

Title: See Remarks

Shares: 75

Price/Share: $8.47

Value: $635.25

Shares Owned: 8,557

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-18	Brady, Kelly	Officer	See Remarks	Direct	Sale	59	7.53	$444.27	8,562	4
2026-05-18	Henn, Matthew R	Officer	See Remarks	Direct	Sale	77	7.53	$579.81	7,838	4
2026-05-18	Shaff, Eric D.	Director	-	Direct	Sale	259	7.53	$1,950.27	12,040	4
2026-05-18	Desrosier, Thomas	Officer	See Remarks	Direct	Sale	79	7.53	$594.87	7,954	4
2026-02-15	Young, Teresa L.	Officer	See Remarks	Direct	Sale	75	8.47	$635.25	8,557	4
2026-02-15	Desrosier, Thomas	Officer	See Remarks	Direct	Sale	78	8.47	$660.66	7,789	4
2026-02-15	Shaff, Eric D.	Director	-	Direct	Sale	259	8.47	$2,193.73	11,577	4
2026-02-15	Henn, Matthew R	Officer	See Remarks	Direct	Sale	89	8.47	$753.83	7,677	4
2025-11-15	Desrosier, Thomas	Officer	See Remarks	Direct	Sale	76	17.30	$1,314.80	7,623	4
2025-11-15	Young, Teresa L.	Officer	See Remarks	Direct	Sale	1,042	17.30	$18,026.60	8,401	4
2025-11-15	Henn, Matthew R	Officer	See Remarks	Direct	Sale	1,257	17.30	$21,746.10	7,527	4
2025-11-15	Shaff, Eric D.	Director	-	Direct	Sale	217	17.30	$3,754.10	11,113	4
2025-08-18	Henn, Matthew R	Officer	See Remarks	Direct	Sale	73	16.65	$1,215.45	4,548	4
2025-08-18	Shaff, Eric D.	Director	-	Direct	Sale	217	16.65	$3,613.05	10,609	4
2025-08-18	Young, Teresa L.	Officer	See Remarks	Direct	Sale	59	16.65	$982.35	5,215	4
2025-08-18	Desrosier, Thomas	Officer	See Remarks	Direct	Sale	76	16.65	$1,265.40	7,455	4
2025-05-16	Young, Teresa L.	Officer	See Remarks	Direct	Sale	63	7.28	$458.64	5,044	4
2025-05-16	Henn, Matthew R	Officer	See Remarks	Direct	Sale	77	7.28	$560.56	4,383	4
2025-05-16	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	220	7.28	$1,601.60	10,102	4
2025-05-15	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	79	7.28	$575.12	7,287	4
2025-02-18	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	3,953	0.81	$3,201.93	84,443	4
2025-02-18	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	12,726	0.81	$10,308.06	192,039	4
2025-02-18	Young, Teresa L.	Officer	See Remarks	Direct	Sale	3,338	0.81	$2,703.78	97,536	4
2025-02-18	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	4,300	0.81	$3,483.00	142,456	4
2025-02-18	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	4,416	0.81	$3,576.96	39,875	4
2024-11-18	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	927	0.54	$500.58	77,770	4
2024-11-18	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	878	0.54	$474.12	135,192	4
2024-11-18	Young, Teresa L.	Officer	See Remarks	Direct	Sale	735	0.54	$396.90	90,404	4
2024-11-18	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	977	0.54	$527.58	32,415	4
2024-11-18	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	2,505	0.54	$1,352.70	170,389	4
2024-10-28	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	4,259	0.69	$2,938.71	133,414	4
2024-10-28	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	3,984	0.69	$2,748.96	75,885	4
2024-10-28	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	4,334	0.69	$2,990.46	30,423	4
2024-10-28	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	8,748	0.69	$6,036.12	165,082	4
2024-10-28	Young, Teresa L.	Officer	See Remarks	Direct	Sale	2,983	0.69	$2,058.27	88,483	4
2024-08-16	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	923	0.84	$775.32	67,247	4
2024-08-16	Young, Teresa L.	Officer	See Remarks	Direct	Sale	728	0.84	$611.52	80,106	4
2024-08-16	Ege, David S.	Officer	See Remarks	Direct	Sale	1,128	0.84	$947.52	77,575	4
2024-08-16	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	873	0.84	$733.32	124,173	4
2024-08-16	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	973	0.84	$817.32	21,013	4
2024-08-16	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	2,518	0.84	$2,115.12	145,993	4
2024-08-05	Young, Teresa L.	Officer	See Remarks	Direct	Sale	24,480	1.08	$26,438.40	78,178	4
2024-05-15	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	2,435	0.94	$2,288.90	140,698	4
2024-05-15	Young, Teresa L.	Officer	See Remarks	Direct	Sale	703	0.94	$660.82	17,658	4
2024-05-15	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	891	0.94	$837.54	65,357	4
2024-05-15	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	843	0.94	$792.42	122,390	4
2024-05-15	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	939	0.94	$882.66	19,017	4
2024-05-15	Ege, David S.	Officer	See Remarks	Direct	Sale	1,090	0.94	$1,024.60	75,734	4
2024-02-16	Young, Teresa L.	Officer	See Remarks	Direct	Sale	3,374	1.08	$3,643.92	15,705	4
2024-02-16	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	11,549	1.08	$12,472.92	135,321	4
2024-02-16	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	4,170	1.08	$4,503.60	63,436	4
2024-02-16	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	4,400	1.08	$4,752.00	16,988	4
2024-02-16	Ege, David S.	Officer	See Remarks	Direct	Sale	5,010	1.08	$5,410.80	73,856	4
2024-02-16	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	3,939	1.08	$4,254.12	120,577	4
2024-02-16	Arkowitz, David	Officer	Chief Financial Officer	Direct	Sale	3,939	1.08	$4,254.12	182,442	4
2023-10-30	Von, Moltke Lisa	Officer	See Remarks	Direct	Sale	4,232	1.35	$5,713.20	9,513	4
2023-10-30	Shaff, Eric D.	Director,Officer	CEO and President	Direct	Sale	8,552	1.35	$11,545.20	115,620	4
2023-10-30	Desrosier, Thomas	Officer	Chief Legal Officer and EVP	Direct	Sale	4,156	1.35	$5,610.60	113,891	4
2023-10-30	Ege, David S.	Officer	See Remarks	Direct	Sale	4,066	1.35	$5,489.10	66,991	4
2023-10-30	Cloghessy, Paula	Officer	See Remarks	Direct	Sale	2,904	1.35	$3,920.40	45,684	4
2023-10-30	Arkowitz, David	Officer	Chief Financial Officer	Direct	Sale	4,066	1.35	$5,489.10	175,756	4
2023-10-30	Henn, Matthew R.	Officer	See Remarks	Direct	Sale	3,886	1.35	$5,246.10	56,356	4
2023-10-30	Young, Teresa L.	Officer	See Remarks	Direct	Sale	2,907	1.35	$3,924.45	8,454	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

24.07%

Inst. Shares: 2,306,463

Shares Outstanding: 9,582,533

2025-12-31

27.56%

Inst. Shares: 2,441,565

Shares Outstanding: 8,858,975

2025-09-30

24.24%

Inst. Shares: 2,123,038

Shares Outstanding: 8,758,692

2025-06-30

26.13%

Inst. Shares: 2,284,938

Shares Outstanding: 8,743,733

2025-03-31

Inst. Shares: 61,282,182

Shares Outstanding: 8,703,221

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	2,306,463	9,582,533	24.07%
2025-12-31	2,441,565	8,858,975	27.56%
2025-09-30	2,123,038	8,758,692	24.24%
2025-06-30	2,284,938	8,743,733	26.13%
2025-03-31	61,282,182	8,703,221	-
2024-12-31	62,866,002	7,769,910	-
2024-09-30	63,088,030	7,632,242	-
2024-06-30	68,437,893	7,575,620	-
2024-03-31	83,487,140	7,305,026	-
2023-12-31	85,552,575	128,003,294	66.84%
2023-09-30	103,799,966	128,289,871	80.91%
2023-06-30	109,140,613	127,713,486	85.46%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Seres Therapeutics, Inc. (MCRB) — SEC Financial Statements & Analysis

Seres Therapeutics, Inc. (MCRB) is a pharmaceutical preparations company, incorporated in DE. Seres Therapeutics, Inc. trades on Nasdaq as: MCRB. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Seres Therapeutics, Inc. reported a 448.44% year-over-year revenue growth, a Debt-to-Equity ratio of 1.94x, a Price-to-Sales (P/S) ratio of 40.67x (TTM), a Price-to-Book (P/B) ratio of 2.22x (TTM), at a market cap of $76.58M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 448.44%
Debt To Equity: 1.94x
P/S TTM: 40.67x
P/B TTM: 2.22x
Market Cap: $76.58M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Seres Therapeutics, Inc. in?

Seres Therapeutics, Inc. (MCRB) operates in the Pharmaceutical Preparations industry.

What is MCRB's market cap?

Seres Therapeutics, Inc. (MCRB) has a market capitalization of $76.58M as of 2026-06-30.

What is MCRB's P/E ratio?

Seres Therapeutics, Inc. (MCRB)'s trailing twelve month P/E ratio is 2.54x as of 2026-06-30.

What exchange does MCRB trade on?

Seres Therapeutics, Inc. (MCRB) trades on the Nasdaq.

Where is Seres Therapeutics, Inc. incorporated?

Seres Therapeutics, Inc. is incorporated in DE.